Discounted Cash Flow (DCF) Analysis Unlevered
Immix Biopharma, Inc. (IMMX)
$1.97
-0.07 (-3.43%)
All numbers are in Millions, Currency in USD
Operating Data
Year A/P | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | |||||||||
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBITDA (%) | |||||||||
| EBIT | - | - | - | - | - | - | - | - | - |
| EBIT (%) | |||||||||
| Depreciation | - | - | - | - | - | - | - | - | - |
| Depreciation (%) |
Balance Sheet Data
Year A/P | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Total Cash | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|
| Total Cash (%) | |||||||||
| Account Receivables | - | - | - | - | - | - | - | - | - |
| Account Receivables (%) | |||||||||
| Inventories | - | - | - | - | - | - | - | - | - |
| Inventories (%) | |||||||||
| Accounts Payable | - | - | - | - | - | - | - | - | - |
| Accounts Payable (%) | |||||||||
| Capital Expenditure | - | - | - | - | - | - | - | - | - |
| Capital Expenditure (%) |
Weighted Average Cost Of Capital
| Share price | $ 1.97 |
|---|---|
| Beta | 0.000 |
| Diluted Shares Outstanding | 13.89 |
| Cost of Debt | |
| Tax Rate | -0.12 |
| After-tax Cost of Debt | 5.00% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 3.784 |
| Total Debt | - |
| Total Equity | 27.36 |
| Total Capital | 27.36 |
| Debt Weighting | 0.00 |
| Equity Weighting | 100.00 |
| Wacc |
Build Up Free Cash
Year A/P | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - | - | - | - |
| Tax Rate | -2.16% | -1.55% | -0.02% | -0.12% | -0.97% | -0.97% | -0.97% | -0.97% | -0.97% |
| EBIAT | - | - | - | - | - | - | - | - | - |
| Depreciation | - | - | - | - | - | - | - | - | - |
| Accounts Receivable | - | - | - | - | - | - | - | - | - |
| Inventories | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - |
| Capital Expenditure | -0.01 | - | -0 | - | - | - | - | - | - |
| UFCF | - | - | - | - | - | - | - | - | - |
| WACC | |||||||||
| PV UFCF | - | - | - | - | - | - | - | - | - |
| SUM PV UFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 3.78 |
| Free cash flow (t + 1) | - |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -13.44 |
| Equity Value | - |
| Shares Outstanding | 13.89 |
| Equity Value Per Share | - |